BioSpace News Archive

Seagen Announces Long-Term Results from TUKYSA ® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting - Updated Analysis Shows Median Overall Survival for TUKYSA Arm Extended to Two Years, with Benefit Maintained Across All Prespecified Patient Subgroups in HER2CLIMB Trial -

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable growth and value,” said Rob Davis, president, M

London, UK, 3 June 2021 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, announces the appointment of Stefan König as Chief Executive Officer.

BioCryst Pharmaceuticals, Inc. announced that oral, once-daily ORLADEYO™ is now available for patients with a prescription in Germany.

Talaris Therapeutics, Inc. announced upcoming presentations of data from the company’s Phase 2 study of FCR001 at the American Transplant Congress taking place virtually June 4-9, 2021.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the Company plans to participate in the 42nd Annual Goldman Sachs Global Healthcare Conference.

Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, announced that members of its executive management team will be presenting at the 2021 LD Micro Invitational XI on June 10th at 2:30pm EDT.

The partnership will help serve a dire need for surface disinfectant treatments to prevent the spread of highly infectious diseases to vulnerable populations in developing nations

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company will participate in the following investor conferences in June

Confirmatory Phase 3 Study, RALLY, Ongoing with Interim Analysis Expected in Third Quarter 2021